J&J Hip Designer Says He Gave Complaints to Marketers

By Maurice Possley & David Voreacos A California surgeon who designed Johnson & Johnson’s (JNJ) recalled metal hips testified that he gave complaints about the devices ...

5 Can’t-Miss Health-Care Events This Week

By Sean Williams Normally we have a nice blend of health-care events to take notice of each week. This week I’m steering you squarely toward the biotechnology sector, which has ...

SP-333 Targets Root Cause Of Irritable Bowel Syndrome

By Jordo Bivona Irritable bowel syndrome has no organic cause and treating it usually depends on reducing symptoms of chronic abdominal pain, bloating, and gastric discomfort. While ...

Dendreon Earnings: An Early Look

By Dan Caplinger Earnings season is now starting to wind down, with most companies already having reported their quarterly results. But there are still some companies left to report, ...

Strides Arcolab looks to sell stake worth Rs 4,885 cr

The Bangalore-based pharma company is in talks with Japan’s Otsuka Holdings By Raghuvir Badrinath Strides Arcolab, the Bangalore-based publicly-held pharmaceutical company, is understood ...

Glaxo Sued By Maryland AG Over Avandia Risks

By Ed Silverman So $3 billion may be a large sum of money, but this does not make everything go away. Having paid that much last year to the US federal government to resolve a bushel ...

J&J stakes out Boston/Cambridge HQ for new innovation center

By John Carroll J&J ($JNJ) is making a big entrance in the Boston/Cambridge hub. The Boston Business Journal reports today that the pharma giant has taken a lease on new digs ...

Upstart Blaze banks $8.5M A round for new cancer surgery tech

By John Carroll Seattle-based startup Blaze Bioscience has nailed an $8.5 million A round, giving it the money it needs to hire on a pair of key players, lease a new lab and headquarters ...

Report: Booming Genentech plans 600 new hires in 2013

By John Carroll Genentech is on a roll. And it’s looking for hundreds of new staffers to keep its drug development efforts in overdrive. Tapped as Roche’s U.S. biologics R&D ...

Roche/Genentech’s breakthrough T-DM1 wins blockbuster OK for breast cancer

By John Carroll The FDA today approved T-DM1, a breakthrough antibody drug conjugate from Roche/Genentech widely expected to quickly become a new blockbuster treatment for breast ...

Roche produces ‘hidden billionaires’ as cancer drugs dominate

Today’s approval of Kadcyla adds to the wealth By Eric Palmer Roche ($RHHBY) shares quickly ticked up today after the FDA approved its highly anticipated breast treatment Kadcyla. ...

Warburg persists in trying to unload Bausch + Lomb

Sources again talking freely about private considerations By Eric Palmer It was probably a good indication of just how poorly a possible sale of Bausch + Lomb was shaping up when ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS